Filing Details
- Accession Number:
- 0001209191-20-021385
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-27 16:19:44
- Reporting Period:
- 2019-11-07
- Accepted Time:
- 2020-03-27 16:19:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750019 | Tcr2 Therapeutics Inc. | TCRR | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1555918 | W Neil Gibson | C/O Tcr2 Therapeutics 100 Binney Street Cambridge MA 02142 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-11-07 | 212,560 | $0.00 | 493,791 | No | 4 | J | Indirect | see footnote (2) |
| Common Stock | Disposition | 2019-11-13 | 196,177 | $0.00 | 297,614 | No | 4 | J | Indirect | see footnote (2) |
| Common Stock | Disposition | 2019-11-15 | 217,974 | $0.00 | 79,640 | No | 4 | J | Indirect | see footnote (2) |
| Common Stock | Disposition | 2020-03-13 | 52,000 | $6.52 | 27,640 | No | 4 | S | Indirect | see footnote (2) |
| Common Stock | Disposition | 2020-03-16 | 17,723 | $6.60 | 9,917 | No | 4 | S | Indirect | see footnote (2) |
| Common Stock | Disposition | 2020-03-17 | 3,009 | $6.49 | 6,908 | No | 4 | S | Indirect | see footnote (2) |
| Common Stock | Disposition | 2020-03-18 | 3,120 | $6.83 | 3,788 | No | 4 | S | Indirect | see footnote (2) |
| Common Stock | Disposition | 2020-03-19 | 3,140 | $7.41 | 648 | No | 4 | S | Indirect | see footnote (2) |
| Common Stock | Disposition | 2020-03-20 | 648 | $7.94 | 0 | No | 4 | S | Indirect | see footnote (2) |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | J | Indirect | see footnote (2) |
| No | 4 | J | Indirect | see footnote (2) |
| No | 4 | J | Indirect | see footnote (2) |
| No | 4 | S | Indirect | see footnote (2) |
| No | 4 | S | Indirect | see footnote (2) |
| No | 4 | S | Indirect | see footnote (2) |
| No | 4 | S | Indirect | see footnote (2) |
| No | 4 | S | Indirect | see footnote (2) |
| No | 4 | S | Indirect | see footnote (2) |
Footnotes
- Curative Ventures CT LLC, of which the Reporting Person is a managing member of Curative Ventures CT Ultimate Manager LLC, the general partner of Curative Ventures CT Manager, LP, the manager of Curative Ventures CT LLC, distributed these shares to its members on a pro rata basis, for no consideration.
- The shares are held by Curative Ventures CT LLC. The Reporting Person is a managing member of Curative Ventures CT Ultimate Manager LLC, the general partner of Curative Ventures CT Manager, LP, the manager of Curative Ventures CT LLC and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.415 to $6.526, inclusive.
Billionaire Hedge Funds
